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Candida auris is an emerging multi-drug resistant yeast, that causes major issues
regarding patient treatment and surface disinfection in hospitals. Indeed, an important
proportion of C. auris strains isolated worldwide present a decreased sensitivity to
multiple and sometimes even all available antifungals. Based on recent tentative
breakpoints by the CDC, it appears that in the USA about 90, 30, and < 5% of isolates
have been resistant to fluconazole, amphotericin B, and echinocandins, respectively.
To date, this has lead to a low therapeutic success. Furthermore, C. auris is prone to
cause outbreaks, especially since it can persist for weeks in a nosocomial environment
and survive high-end disinfection procedures. In this review, we describe the molecular
resistance mechanisms to antifungal drugs identified so far in C. auris and compare them
to those previously discovered in other Candida species. Additionally, we examine the
role that biofilm formation plays in the reduced antifungal sensitivity of this organism.
Finally, we summarize the few insights on how this yeast survives on hospital surfaces
and discuss the challenge it presents regarding nosocomial environment disinfection.
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1. INTRODUCTION
In the last decade, an emerging nosocomial Candida species has been causing severe cases of
candidemia and other types of fungal infections. Outbreaks of the responsible pathogen, namely
Candida auris, have been observed all around the world (see Figure 1A) (Lockhart et al., 2017).
Whole genome sequencing determined the presence of four specific clades within the C. auris
species: East Asia, South Asia, South Africa, and South America. All clades are characterized by
distinct single nucleotide polymorphisms (SNPs), which highlights the independent and worldwide
emergence of this pathogen (Lockhart et al., 2017).
Comparative studies in different animal models (murine and Galleria mellonella larvae) showed
strain-dependant virulence levels for C. auris. In most cases, C.auris strains proved to be less
virulent than C. albicans (Borman et al., 2016; Ben-Ami et al., 2017; Fakhim et al., 2018; Wang
et al., 2018). However, reported cases of C. auris outbreaks were linked with a high mortality
rate, primarily in immunocompromised patients. Other conditions such as diabetes, cardiovascular
and/or pulmonary diseases, sepsis or a prior treatment with antibiotics seemed also to be important
risk factors (Osei Sekyere, 2018).
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FIGURE 1 | (A) Map representing the number of isolates per outbreak since 1996. The first outbreak year is brown-colored and the latest outbreak year is in pink.
Circle size is proportional to the number of isolates reported for each outbreak. Outbreak survey was performed recovering data from three main reviews
(Osei Sekyere, 2018; Jackson et al., 2019; Kenters et al., 2019) and complemented by a pubmed search using the query “Candida” AND “auris” AND “outbreak” as
keywords. Results were limited in time, between the 21/07/2017, the latest study in the systematic review by Osei Sekyere and the 31/08/2019, when the literature
search was performed. Studies not present in the review by Osei Sekyere: (Biswal et al., 2017; Abdalhamid et al., 2018; Adams et al., 2018; Belkin et al., 2018; Chow
et al., 2018; Desoubeaux et al., 2018; Lesho et al., 2018; Mayor, 2018; Parra-Giraldo et al., 2018; Ruiz-Gaitán et al., 2018, 2019a,b; Sexton et al., 2018; Adam et al.,
2019; Barantsevich et al., 2019; Escandón et al., 2019; Leach et al., 2019; O’Connor et al., 2019; Park et al., 2019; Sana et al., 2019; Sayeed et al., 2019). (B) MIC
ranges for three antifungals measured in C. auris isolates from different outbreaks around the world. The red dotted line represents the tentative breakpoint proposed
by the CDC. IPSV is an acronym for “India, Pakistan, South Africa, and Venezuela,” as strains from these countries were all analyzed in the same study. Outbreak
survey was performed identically to (A). Only outbreak with >1 isolate were plotted. Studies cited by Osei Sekyere are signaled with [OS] and studies cited by Kenters
et al. with [KE].
Exceptionally for a yeast, C. auris has successfully spread in
nosocomial environments. For example, in a UK hospital, a single
patient colonized with C. auris led to subsequent identifications
of other cases among other hospitalized patients. The pathogen
was also detected on the healthcare staff even several months
after its first isolation, suggesting an efficient human to human
transmission. Additionally, traces of C. auris had been found
on bed sides, windowsills, monitors, and other equipment
throughout the hospital, showing that C. auris is capable to
persist on nosocomial surfaces (Schelenz et al., 2016), in contrast
to other Candida species. Investigation into an outbreak in
another UK hospital reported that the use of reusable equipment
such as axillary temperature probes was the primary cause of
transmission to patients (Eyre et al., 2018), further illustrating its
capability to survive on surfaces.
The capacity to survive in nosocomial environments could be
due to the ability of C. auris to form biofilms; a growth form in
which cells are arranged together in microcolonies protected by a
matrix of glucan. By convention, cells enclosed in the matrix are
called sessile, and cells outside of it are called planktonic. C. auris
cells protected by this structure were proven to be difficult to
eliminate, even with high-levels of disinfection procedures (Kean
et al., 2018b).
In addition to potentially allowing an increased survival on
inert surfaces, the ability of C. auris to form biofilms may also
be an important factor of its resistance to systemic antifungals
used in patient treatment. Indeed, the fact that biofilm forming
cells were isolated from wounds and catheter tips indicates that
some C. auris cells could survive in biofilm-form in patients
(Borman et al., 2016) and it was shown that sessile cells presented
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reduced susceptibility for several antifungals. (Sherry et al., 2017).
Finally, biofilm has also been shown to be an important virulence
factor, as biofilm forming C. auris strains are linked to increased
morbidity and mortality (Borman et al., 2016).
With this review we aim to highlight molecular resistance
mechanisms acquired by C. auris, which led to its extraordinary
survival in nosocomial environment and in hospitalized patients.
2. C. AURIS ANTIFUNGAL
SUSCEPTIBILITY
After 10 years of recording minimum inhibitory concentration
(MIC) for available antifungals, the CDC recently published a
tentative of breakpoints to better define C. auris antifungal
susceptibility1. It clearly appeared that C. auris has exceptionally
high MICs for the four main classes of antifungal drugs:
azoles, echinocandins, polyenes (Figure 1B), and nucleoside
analogs. In this chapter, we will examine in detail two factors
that proved to play a role in this decreased susceptibility to
antifungal treatments: molecular resistance mechanisms and
biofilm-associated resistance mechanisms.
2.1. Molecular Resistance Mechanisms
We define here molecular resistance as the ways individual
cells can decrease their sensitivity to antifungals due to genetic
modifications leading to drug target modification, efflux pumps
overexpression, or metabolism modifications (see for review:
Pemán et al., 2009; Sanglard et al., 2009; Krishnasamy et al.,
2018). This section compiles, for each class of antifungal, the
main molecular resistance mechanisms found in C. auris up to
now. Additionally, Table 1 summarizes for each drug, the mode
of action, the related resistance mechanisms described in non-
auris Candida and the resistance mechanisms discovered in C.
auris, as of yet.
2.1.1. Mechanisms of Resistance to Azoles
2.1.1.1. MFS and ABC efflux pumps overexpression
Efflux pumps are proteins that transport components across the
cell membrane. Some of them can pump drugs outside of the
cell, lowering their concentration and effect on the cell. There
are two major families of efflux pumps involved in antifungal
resistance: ATP Binding Cassette (ABC) and Major Facilitator
Superfamily (MFS) transporters. Enhanced overexpression of
efflux pumps is one of the major resistance mechanism to azoles
in pathogenic Candida species (Schuetzer-Muehlbauer et al.,
2003; Morschhäuser et al., 2007).
Indian strains of C. auris sequenced in two different
studies exhibit numerous genes orthologous to ABC and MFS
transporters of C. albicans (Chatterjee et al., 2015; Sharma et al.,
2016). Interestingly, C. auris strains that were isolated in Israel
showed an intrinsicly high ABC transporter activity compared
to C. glabrata and C. haemulonii, by measuring efflux of a
fluorescent substrate (Rhodamine 6G) (Ben-Ami et al., 2017).
1CDC (2019). Antifungal Susceptibility Testing and Interpretation. Available
online at: https://www.cdc.gov/fungal/candida-auris/c-auris-antifungal.html
(accessed April 29, 2019).
In C. albicans, CDR1 is a gene encoding for an ABC efflux
pump, known for its role in azole resistance (Sanglard et al.,
1995). A gene homologous toCDR1was found inC. auris. (Rybak
et al., 2019). The same study also showed that the deletion of this
gene could increase susceptibility of resistant strains from 64- to
128-fold (Rybak et al., 2019).
2.1.1.2. Point mutations in ERG11
Ergosterol is a key membrane component in fungi. In Candida
spp., its biosynthesis is mediated, among others, by the enzyme
Lanosterol 14-alpha-demethylase (LD), encoded by the gene
ERG11 which converts lanosterol to ergosterol. The LD is the
primary target of azoles, antifungals that inhibit the function of
the enzyme and effectively shut down ergosterol biosynthesis,
thus impairing membrane integrity (Sanglard et al., 1998).
Point mutations in ERG11 have been shown to reduce azole
sensitivity in Candida spp., particularly in three “hot-spot”
regions located between amino-acids 105–165, 266–287, and
405–488 (Vandeputte et al., 2012).
Interestingly, after having retrieved the amino acid sequences
of 44 C. auris isolates from India, 15 missense mutations were
found when aligned to the C. albicans wild-type ERG11 sequence
(Chowdhary et al., 2018). Five of these mutations were already
associated with azole resistance in C. albicans. Among these
variants two were found in every resistant strain tested in this
study, namely Y132F or K143R (Chowdhary et al., 2018). It can
also be noted that these mutations are in the first “hot spot”
discussed earlier.
A screen for variants in the ERG11 gene of C. auris
strains from Columbia identified the same Y132F and K143R
substitutions. Upon heterologous expression of these two
mutations in S. cerivisiae, MICs for azoles presented a two-
fold increase as compared to S. cerevisiae strains expressing the
wild-type C. auris ERG11 gene (Healey et al., 2018).
2.1.1.3. ERG11 overexpression
In C. albicans, an overexpression of ERG11 has been linked to
a resistance to azole treatment as well.The increased production
of LD overwhelms the capacity of the antifungal to inhibit the
activity of the protein, resulting in an active protein despite drug
treatment (Lopez-Ribot et al., 1998).
In C. auris, real time PCR experiments showed that in absence
of fluconazole, there was no difference in ERG11 expression
between fluconazole-susceptible and fluconazole-resistant strains
(Chowdhary et al., 2018). In presence of the antifungal, ERG11
expression rises in resistant strains when compared to a control
without fluconazole (Chowdhary et al., 2018). However, the effect
of this drug on ERG11 expression was not tested on susceptible
strains. Therefore, conditionally increased expression of ERG11
in presence of fluconazole has not been demonstrated to be
specific to resistant strains, until now.
2.1.2. Mechanisms of Resistance to Echinocandins
Beta(1,3)D-glucan is a key component of the fungal cell
wall and is encoded by the FKS1 and FKS2 genes, two
subunits of the Beta(1,3)D-glucan synthase. Echinocandins
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TABLE 1 | Pharmacodynamics of the four main antifungal classes and linked resistance mechanisms in Candida spp. in general and C. auris specifically.
Antifungal
class
Target Effect Resistance mechanism(s)


















MSF efflux pumps overexpression
due to mutation in Mrr1
transcription factor (TF). [a]
CDR genes overexpression,
encoding ABC efflux pumps,
due to mutation in Tac1 TF. [a]
Point mutation in gene
encoding LD (ERG11)
Upregulation of ERG11 due
to mutation in Upc2 TF. [a]
ERG3 mutation:Bypass ergosterol
synthesis pathway to prevent
toxic compound accumulation
Presence of MFS efflux
pumps genes [b].





ERG11 point mutation :
Y132F ; [f]
K143R [f]








Mutation in FKS1 and FKS2 gene,
encoding the target enzyme
Presence of FKS1 and FKS2
In FKS1 three mutations














to reduce target exposition
Increase catalase activity to
counter oxidative damage
5 SNPs in different genomic













Modification of enzymes involved
in 5-FC uptake or metabolism
Competitive inhibition of 5-FC
effect by increased pyrimidine
synthesis
Amino-acid substitution
(F211I) in FUR1, a gene
involved in 5-FC metabolism
found in a single flucytosine-
resistant isolate [g]
Adapted from Krishnasamy et al. (2018). With additional information from: [a] Vandeputte et al. (2012), [b] Sharma et al. (2016), [c] Ben-Ami et al. (2017), [d] Chowdhary et al. (2018),
[e] Rybak et al. (2019), [f] Healey et al. (2018), [g] Rhodes et al. (2018), [h] Kordalewska et al. (2018), [i] Escandón et al. (2019).
inhibit this enzyme, decreasing the amount of glucans in the cell
wall (Martins et al., 2011).
In C. albicans and other non-auris Candida species, several
mutations leading to echinocandin resistance were found in the
same two regions of FKS1 and FKS2. So, they were named
“hot-spots” 1 and 2 (HS1 and HS2). In the C. albicans FKS1
gene these “hot-spots” are located between amino acids 641–
649 and 1,345–1,365 (Park et al., 2005). Sequencing of the
corresponding hot-spot regions of 38 C. auris strains lead
to the discovery of an S639F amino acid substitution that
is correlated with pan-echinocandin resistance: it was present
in all four resistant strains and absent in the 34 susceptible
ones. This position in C. auris FKS1 is aligned to the position
645 (also a Serine) in C. albicans (Chowdhary et al., 2018).
Interestingly, this mutation is in the region aligning to the
HS1 of C. albicans FKS1. Other studies observed different
mutations at the same location in echinocandin-resistant C. auris
strains: S639Y and S639P (Rhodes et al., 2018). The latter was
confirmed to cause echinocandin resistance in vivo in a mouse
model (Kordalewska et al., 2018).
FKS2 was also found in a single copy in the C. auris
genome (Sharma et al., 2016), but no mutation associated
with echinocandin resistance were found in this gene to
our knowledge.
2.1.3. Mechanisms of Resistance to Polyenes
As shown in the Figure 1B, several C. auris strains are
resistant to Amphotericin B (AMB). In the Candida species,
modifications of the sterol composition of the membrane
have been highlighted as a resistance mechanism (Haynes
et al., 1996; Nolte et al., 1997). In C. albicans, mutations in
ERG 2, 3, 5, 6 or 11 have been shown to have this effect
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(Arendrup and Patterson, 2017). Rhodes et al. screened 27 C.
auris isolates from the UK for SNPs in these genes in strains
displaying reduced sensitivity to AMB. However, no variants
explaining these differences in drug susceptibility were found
(Rhodes et al., 2018).
2.1.4. Mechanisms of Resistance to Flucytosine
(5-Fluorocytosine)
Flucytosine is a nucleoside analog that inhibits nucleic acid
synthesis. After cell entry, flucytosine has to be activated to have
an antifungal effect. This activation requires, among others, the
protein encoded by the gene FUR1Waldorf and Polak (1983). In
non-auris Candida speciesmutations in FUR1were demonstrated
to be linked with flucytosine resistance (Vandeputte et al., 2012).
Rhodes et al. sequenced a flucytosine resistant C. auris strain
and observed a F211I amino acid substitution in the FUR1 gene
(Rhodes et al., 2018). This specific missense mutation has no
known equivalent in other Candida species, therefore additional
studies are required to determine if this mutation is the cause of
the resistance to flucytosine in the tested C. auris strain (Rhodes
et al., 2018). However, this drug is less employed than other
antifungals. Because of that, fewer studies have been performed
to better understand the resistance of C. auris to this compound.
To summarize, some resistance mechanisms previously
discovered in Candida species like C. glabrata and C. albicans,
were also showcased by C. auris. They are listed in the last
column of the Table 1. However, C. auris antifungal resistance is
only partially explained by these previously described resistance
mechanisms. In order to eventually design new therapeutic
agents andmore generally to improve patient care, further studies
are needed to better understand the underlying mechanisms
leading to the exceptionally high MIC ranges presented by some
C. auris strains (see Figure 1B).
2.2. Biofilm: An Antifungal Resistant Way of
Life
It was shown that MICs for several antifungals are higher in
C. auris sessile cells (up to 4-, 20-, 60-fold for voriconazole,
Amphotericin B, and Micafungin, respectively) compared to
planktonic cells (Sherry et al., 2017). Similarly, minimal biofilm
eradication concentrations were shown to be 512-fold higher
than MICs for echinocandins and azoles (Romera et al., 2019).
This phenomenon was previously shown for C. albicans (Hawser
and Douglas, 1995). The molecular mechanisms responsible for
these elevated MIC are still largely unknown in C. auris but some
studies have already provided some insights.
MSF and ABC efflux pump-encoding genes were found
to be upregulated (2- to 4-fold) in sessile cells compared to
planktonic cells (Kean et al., 2018a). Concordantly, the activity
of corresponding proteins was 2-fold increased. However, when
treated with efflux pump inhibitors the antifungal sensitivity of
sessile cells was increased 4- to 16-fold after 12 h. This suggests
that efflux pumps play an important role in the resistance to
antifungals displayed by this type of cells (Kean et al., 2018a).
In C. albicans, the exopolymer matrix is known to non-
specifically bind to all classes of antifungals and sequestrate them
outside the cells (Nett et al., 2010). As Candida spp. share a
core polysaccharide profile, it was suggested that this mechanism
might be conserved in C. auris as well (Kean et al., 2018a). This
was later confirmed in in vivo and in vitro assays (Dominguez
et al., 2019).
3. NOSOCOMIAL PERSISTENCE
The capacity of C. auris to colonize and persist on surfaces
is exceptional: it is able to persist longer on moist surfaces in
comparison to C. albicans (Piedrahita et al., 2017). It also has a
prolonged metabolic activity on surfaces, akin to C. parapsilosis,
a known skin and plastic colonizer (Piedrahita et al., 2017; Welsh
et al., 2017).
The increased survival of C. auris on surfaces was investigated
by two studies. The first claimed it could be linked to an
enhanced environmental stress resistance to temperature and
other stressors (Kean et al., 2018b). The second hypothesizes that
it could be due to the formation of biofilm. However, this remains
to be proven as, so far, no biofilm forming isolate was recovered
from environmental surfaces (Ku et al., 2018). It is to be noted
that these two possibilities are not mutually exclusive, and that
biofilm formation might even be the cause of the increased stress
resistance (Ku et al., 2018).
The persistence of C. auris in nosocomial environments is
heightened by the resistance of this pathogen to disinfection
procedures. The efficacy of NaOCl and peracetic acid on stainless
steel, polymer (polyester coverslips) and cellulose surfaces were
tested. Both disinfectants showed a significant efficacy to kill C.
auris cells on all surfaces. However, some viable cells remained
after applying NaOCl on non-porous surfaces (stainless steel
and polyester coverslips). In fact, higher concentrations of this
disinfectant coupled to longer exposure times were required to
lower regrowth, but even then, they were not able to completely
eradicate the pathogen. For example, a 10,000 parts per million
(ppm) NaOCl concentration coupled to a 5 min exposure on
stainless steel, was enough to observe a significant reduction
of colonies. However, substantial regrowth was observed after
re-inoculation onto a rich medium (Kean et al., 2018b).
For peracetic acid, which is a high-level disinfectant, this
regrowth was surface dependent, as no regrowth was observed for
polymer as opposed to stainless steel. They performed the same
experiments on C. glabrata and C. albicans and obtained similar
results (Kean et al., 2018b).
This shows that high-level disinfection procedures may be
insufficient for a complete surface cleansing and that the pre-
established guidelines for surface disinfection have to be adapted
to these Candida species (Kean et al., 2018b). Factors like the
type of surfaces and exposure times should be considered when
implementing these disinfection procedures (Kean et al., 2018b;
Ku et al., 2018) not only cost and ease of use, as is it often the case
(Ku et al., 2018).
Based on the results of two studies (Cadnum et al., 2017;
Rutala et al., 2019), the CDC recommends using disinfectants
effective against Clostridioides difficile spores. If not possible,
they suggest alternatives such as hydrogen peroxyde 0.5–
1.4% or quaternary ammonium compounds supplemented with
Frontiers in Microbiology | www.frontiersin.org 5 November 2019 | Volume 10 | Article 2788
Chaabane et al. Candida auris Antifungal Resistance
isopropyl alcohol and/or ethyl alcohol2. Finally, ultraviolet-
C light could also be an interesting candidate for surfaces
disinfection. It proved highly effective at killing C. auris colonies,
given sufficient exposure time and distance. However, further
studies would be necessary before implementing such methods
in hospital settings (de Groot et al., 2019).
4. CONCLUSION
The pathogenic and virulent capacities of C. auris are profoundly
worrying. Especially since outbreaks occurred independently in
different regions of the world and that the associated isolates
showed decreased susceptibility to the most commonly used
antifungal drugs used for patient treatment (see Figure 1).
To explain the reduced antifungal susceptibility in C. auris,
researchersmade use of the extended knowledge already available
on other Candida species, particularly C. albicans. As a result,
some of the resistance mechanisms of C. auris were highlighted
(see Table 1). More precisely, two point mutations in ERG11 and
the overexpression of the ABC transporter Cdr1 were proven
to decrease fluconazole sensitivity. Furthermore, an amino acid
substitution in FKS1 was shown to reduce the sensitivity of C.
auris to echinocandins, which is normally the drug of choice for
treatment against this pathogen (Bidaud et al., 2018). Finally,
a mutation in FUR1 was identified in a flucytosine resistant C.
auris strain, but remains to be demonstrated as the cause of this
2CDC (2018). Infection Prevention and Control for Candida auris. Available
online at: https://www.cdc.gov/fungal/candida-auris/c-auris-infection-control.
html (accessed November 12, 2019).
reduced sensitivity. Biofilm is thought to be a resistance
mechanism per se as it was shown to decrease drug susceptibility.
However, further research is still necessary to describe the whole
variety of processes that take place in this growth form. It
is important to note that biofilm is a complex structure that
remains poorly understood and difficult to investigate, even in
well-known species such as C. albicans.
The resistance properties of C. auris are coupled to a
propensity to cause nosocomial infections. Its ability to adhere
to a variety of nosocomial surfaces and survive disinfection are
critical propagation factors. The presence of multiple types of
surfaces poses a challenge for clinical institutions, as standard
disinfection procedures are inefficient and unadapted for each
type of them. This problem, also arises from the insufficient
research on this subject. In addition, a better understanding
of the mechanisms underlying C. auris disinfectant resistance
would help to improve hygiene protocols and avoid future
nosocomial outbreaks.
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